Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 17/20 | 0.72 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.72 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2073883 | 0.85 | SLC6A4 (0.72) | SLC6A2SLC6A4HTR2AHRH1 | |
| SCHEMBL2074806 | 0.85 | SLC6A2 (0.80) | SLC6A2SLC6A4 | |
| SCHEMBL2074980 | 0.84 | SLC6A2 (1.00) | SLC6A2SLC6A4HTR2AHRH1 | |
| SCHEMBL6047909 | 0.84 | SLC6A2 (1.00) | SLC6A2SLC6A4 | |
| SCHEMBL12933730 | 0.83 | SLC6A2 (0.69) | SLC6A2SLC6A4HTR2AHRH1 | |
| SCHEMBL2071888 | 0.83 | SLC6A2 (0.69) | SLC6A2SLC6A4 | |
| SCHEMBL2073824 | 0.82 | SLC6A2 (0.67) | SLC6A2SLC6A4HTR2AHRH1 | |
| SCHEMBL28389561 | 0.81 | SLC6A2 (0.55) | SLC6A2SLC6A4HTR2AHRH1 | |
| SCHEMBL3225503 | 0.78 | SLC6A2 (0.72) | SLC6A2SLC6A4HTR2AHRH1 | |
| SCHEMBL2074199 | 0.78 | SLC6A4 (0.72) | SLC6A2SLC6A4HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1732887-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | Wyeth (US) | 2006-12-20 | — | — | EP | claimed |
| WO-2005097744-A1 | 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) | WYETH (US) | 2005-10-20 | — | — | WO | claimed |